Extended Data Fig. 8: The association of intestinal microbiota and clinical response in recipients of CD19 CAR T cells, including subset analysis institution.
From: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
(A to E) All data reported in this figure are based on 16S rRNA gene sequencing data. (A) Inverse Simpson diversity index of the fecal microbiome in the baseline fecal samples by institution, MSK (n = 26) and Penn (n = 19), compared to healthy volunteers (n = 30) by two-sided Wilcoxon rank-sum test. The middle line is the median, the box limits represent the upper and lower quartiles, the whiskers note 1.5x the interquartile range, and the dots represent the individual data points. (B to C) Beta-diversity was calculated using the Bray-Curtis dissimilarity between a reference point defined by the average of healthy volunteers and each of 30 samples from healthy volunteers. Healthy volunteers were compared to the 45 baseline patient samples (B) and by institution (MSK n = 26; Penn n = 19) (C) by two-sided Wilcoxon rank-sum test. This healthy volunteer cohort has been investigated in a prior study32. The middle line is the median, the box limits represent the upper and lower quartiles, the whiskers note 1.5x the interquartile range, and the dots represent the individual data points. (D to E) Patient samples with higher (one standard deviation above the mean) (red) or lower (one standard deviation below the mean) (blue) Inverse Simpson diversity index. The coefficients for the predicted probability of (C) Day 100 CR and (D) toxicity by Inverse Simpson diversity index. The coefficients correspond to the Bayesian models for Day 100 CR and toxicity, respectively, in Fig. 3e.
